Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 2798 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Synpromics–AskBio: investment, 201908 acquisition of Synpromics Ltd by Asklepios Biopharmaceutical Inc 2019-08-13
Cavion–Jazz Pharmaceuticals: investment, 201908 acquisition $52.5m upfront + $260m milestones of Cavion Inc by Jazz 2019-08-12
MeiraGTx–SEVERAL: investment, 201908 public offering $75.2m+$11.28m with 3.2m+480k ordinary shares at $23.5/share 2019-08-07
Imcyse–Andrew Lloyd Associates: public relations, 201908 service existent by ALA 2019-08-05
Atlantic Healthcare–Consilium: public relations, 201907 service existent European IR + media relations by CSC 2019-07-31
Atlantic Healthcare–Lazar Partners: public relations, 201907 service existent US IR + media relations by Lazar Partners 2019-07-31
Wellington Partners–Consilium: public relations, 201907 service existent by CSC 2019-07-31
PredictImmune–BGF (GB): investment, 201907 financing round Series B totalling £10m incl new investor BGF 2019-07-30
PredictImmune–Cambridge Innovation Capital: investment, 201907 financing round Series B totalling £10m incl new investor CIC 2019-07-30
PredictImmune–Limewash: public relations, 201907 service existent by Limewash 2019-07-30
PredictImmune–Parkwalk Advisors: investment, 201907 financing round Series B totalling £10m incl existing investor Parkwalk Opportunities Fund 2019-07-30
PredictImmune–SEVERAL: investment, 201907 financing round Series B £10m incl Parkwalk + Cambridge Enterprise + BGF + Cambridge Innovation Capital 2019-07-30
PredictImmune–Univ Cambridge: investment, 201907 financing round Series B totalling £10m incl existing investor Cambridge Enterprise 2019-07-30
Quanta Dialysis Technologies–SEVERAL: investment, 201907 financing round Series C £38m led by Swiss family office + btov Partners 2019-07-29
Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Mallinckrodt–Silence Therapeutics: RNAi drugs, 201907– collab developm + commercialisation $20m upfront + milestones + royalties plus $5m investment 2019-07-18
Silence Therapeutics–Mallinckrodt: investment, 201907 investment £4m with 5m new ordinary shares at 79p/share as part of collab = 6.5% share 2019-07-18
Roche–Sosei: GPCR-targeting drugs, 201907– collab multi-target research + licensing up to >$1b Genentech + Sosei Heptares 2019-07-16
Recursion Pharmaceuticals–SEVERAL: investment, 201907 financing round Series C $121m led by Baillie Gifford 2019-07-15
Vasopharm–Optimum Strategic Communications: public relations, 201907 service existent by Optimum 2019-07-11
Nanoform–Notch Communications: public relations, 201907 service existent by Notch 2019-07-10
Start Codon–Zyme Communications: public relations, 201907 service existent by Zyme 2019-07-10
BioNTech–SEVERAL: investment, 201907 financing round Series B $325m led by existing investor Fidelity Management and Research 2019-07-09
Revolution Medicines–Schroders: investment, 201907 financing round Series C totalling $100m incl existing + co-investor Schroder Adveq 2019-07-09
Breakpoint Therapeutics–Evotec: investment, 201907 first financing round totalling €30m incl co-investor Evotec 2019-07-08
Breakpoint Therapeutics–Medicxi: investment, 201907 first financing round totalling €30m incl lead investor Medicxi 2019-07-08
Breakpoint Therapeutics–Otsuka: investment, 201907 first financing round totalling €30m incl co-investor Taiho Ventures LLC 2019-07-08
Breakpoint Therapeutics–SEVERAL: investment, 201907 first financing round €30m for spin-out from Evotec led by Medicxi + incl Taiho Ventures + Evotec 2019-07-08
Ahren Innovation Capital–SEVERAL: investment, 201907 closing of first fund Ahren LP in excells of £200m 2019-07-01
Antimicrobials Working Group–Entasis Therapeutics: antibiotics, 201907– collab existent Entasis is member of AWG 2019-07-01
Antimicrobials Working Group–Iterum Therapeutics: antibiotics, 201907– collab existent Iterum is member of AWG 2019-07-01
ExpreS2ion Biotech–ERS Genomics: CRISPR technology, 201907– license non-excl €na for use + commercialisation of products from ERS Genomics 2019-07-01
Biodesix–Oncimmune: clinical proteomic cancer test, 201906– collab excl commercialisation of EarlyCDT Lung in US by Biodesix 2019-06-28
Sanifit–Consilium: public relations, 201906 service existent by CSC 2019-06-26
Sanifit–la Caixa: investment, 201906 financing round Series D totalling €55.2m incl existing + lead investor Caixa Capital Risc 2019-06-26
Sanifit–SEVERAL: investment, 201906 financing round Series D €55.2m led by Caixa Capital Risc 2019-06-26
Sanifit–SEVERAL: investment, 201906c capitalisation of €17m of convertible bonds 2019-06-26
Avacta–JSR Corp: cell line development, 201906– CHO cell line development for clinical manufacturing of AVA004 Affimer PD-L1 antagonist by Selexis 2019-06-20
Drax Group–Deep Branch Biotechnology: carbon recycling, 201906– collab research carbon dioxide of power generation for single cell protein production 2019-06-18
ADC Therapeutics–SEVERAL: investment, 201906–201907 financing round Series E expansion $103m bringing total Series E to $303m 2019-06-12
GT Apeiron–Exscientia: drug discovery, 201906– collab AI-based drug discovery using Centaur Chemist incl shares + milestones + royalties 2019-06-11
Yukin Therapeutics–SEVERAL: investment, 201906 financing round €3.3m co-led by Advent France Biotechnology + Medicxi 2019-06-04
Otsuka–LeadXPro: structure-based drug discovery, 201906– collab strategic on membrane protein structure research of Astex + LeadXPro 2019-06-03
Verdel Instruments–Longwall Venture Partners: investment, 201905 seed financing round totalling £230k incl £100k from Longwall Ventures 2019-05-30
Verdel Instruments–SEVERAL: investment, 201905 seed financing round £230k from Longwall Venture Partners + Innovate UK 2019-05-30
Verdel Instruments–United Kingdom (govt): investment, 201905 seed financing round totalling £230k incl investor Innovate UK 2019-05-30
Oxford BioMedica–Novo Group: investment, 201905–201906 investment £45.3m + optional £8.2m with 6.6m+1.2m new shares at £6.9/share 2019-05-28
JnJ–Owlstone: breath analyser, 201905– collab developm breath-based test for early detection of pulmonary hypertension with Actelion 2019-05-20
LifeArc–CPPIB: pembrolizumab, 201905 acquisition of portion of Keytruda royalty interests for $1.297b by CPPIB Credit Europe Sàrl 2019-05-20
Storm Therapeutics–Cambridge Innovation Capital: investment, 201905 financing round Series A extension totalling £14m incl existing investor CIC 2019-05-20
Storm Therapeutics–IP Group: investment, 201905 financing Series A extension totalling £14m incl existing investor IP Group 2019-05-20
Storm Therapeutics–Merck (DE): investment, 201905 financing round Series A extension totalling £14m incl existing investor M Ventures 2019-05-20
Storm Therapeutics–Otsuka: investment, 201905 financing Series A extension totalling £14m incl existing investor Taiho Ventures 2019-05-20
Storm Therapeutics–Pfizer: investment, 201905 financing round Series A extension totalling £14m incl existing investor Pfizer Ventures 2019-05-20
Storm Therapeutics–Seroba: investment, 201905 financing round Series A extension totalling £14m incl new investor Seroba Life Sciences 2019-05-20
Storm Therapeutics–SEVERAL: investment, 201905 financing round Series A extension £14m bringing total round to £30m incl new investor Seroba LS 2019-05-20
Adaptimmune–Alpine Immune Sciences: cell therapy technology, 201905– collab + license to incorporte SIP + TIP technology into SPEAR T-cell therapies 2019-05-15
Symphogen–SEVERAL: investment, 201905– capital increase up to DKK572m incl DKK182m debt conversion from existing shareholders 2019-05-15
Vaccitech–Minapharm: cell line, 201905– license to ProBioGen’s AGE1.CR duck cell line for production of viral vectored vaccines 2019-05-15
United Kingdom (govt)–Congenica: bioinformatics, 201905 supply existent processing of samples for 100,000 Genomes Project for Genomics England 2019-05-14
Philogen–Consilium: public relations, 201905 service existent by CSC 2019-05-13
TreeFrog Therapeutics–Andrew Lloyd Associates: public relations, 201905 service existent by ALA 2019-05-13
OMass–DyNAbind: drug discovery technology, 201905 collab existent with OMass Therapeutics 2019-05-07
Sosei–DyNAbind: drug discovery technology, 201905 collab existent with Sosei Heptares 2019-05-07
AstraZeneca–Transgene: cancer immunotherapy, 201905– collab + license option $10m upfront developm armed oncolytic vaccinia viruses using Invir.IO 2019-05-02
Transgene–Huntsworth: public relations, 201905 service existent by Citigate Dewe Rogerson 2019-05-02
Alentis Therapeutics–High-Tech Gründerfonds: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor HTGF 2019-04-30
Alentis Therapeutics–Instinctif Partners: public relations, 201904 service existent media relations by Instinctif 2019-04-30
Alentis Therapeutics–Schroders: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Schroder Adveq 2019-04-30
Alentis Therapeutics–SEVERAL: investment, 201904 financing round Series A CHF12.5m co-led by BioMedPartners + BB Pureos Bioventures 2019-04-30
Enzyre–Optimum Strategic Communications: public relations, 201904 service existent by Optimum 2019-04-30
Deep Branch Biotechnology–BioCity (GB): investment, 201904 seed financing from BioCity 2019-04-24
Start Codon–Babraham Institute: investment, 201904 seed funding round incl founding investor Babraham Bioscience Technologies 2019-04-23
Start Codon–Cambridge Innovation Capital: investment, 201904 seed funding round incl founding investor CIC 2019-04-23
Start Codon–PERSON: investment, 201904 seed funding round incl founding investor + board chairman Ian Tomlinson 2019-04-23
Start Codon–PERSON: investment, 201904 seed funding round incl founding investor + board director Jonathan Milner 2019-04-23
Start Codon–Roche: investment, 201904 seed funding round incl founding investor Genentech 2019-04-23
Start Codon–SEVERAL: investment, 201904 seed funding round from CIC + Babraham Bioscience + Genentech + J Milner + I Tomlinson 2019-04-23
Poseida Therapeutics–Malin Corp: investment, 201904 financing round Series C totalling $142m incl existing + co-investor Malin Corp 2019-04-22
Boehringer–PureTech Health: cancer immunotherapy, 201904– colllab research up to $226m + royalties using lymphatic targeting platform for I-O drugs 2019-04-17
Catalent–Leonard Green & Partners: investment, 201904– up to $1b convertible preferred stock with $650m issued 2019-04-15
Paragon Bioservices–Catalent: investment, 201904– acquisition 100% for $1.2b in cash on cash-free + debt-free basis 2019-04-15
AgomAb Therapeutics–Instinctif Partners: public relations, 201901 service existent by Instinctif für UK + RoW 2019-04-03
Cambridge Innovation Capital–SEVERAL: investment, 201904 financing round £150m with Univ Cambridge as cornerstone investor 2019-04-01
Cambridge Innovation Capital–Univ Cambridge: investment, 201904 financing round totalling £150m incl cornerstone investor Univ Cambridge 2019-04-01
Digital China Health–Congenica: bioinformatics, 201904 collab existent DCH is commercial partner for Sapientia s/w in China 2019-04-01
Karuna–PureTech Health: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor PureTech Health 2019-04-01
Karuna–SEVERAL: investment, 201903–201904 financing round Series B $80m led by ARCH Venture Partners incl $5m debt conversion 2019-04-01
Karuna–Wellcome Trust: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor Wellcome Trust 2019-04-01
Mogrify–United Kingdom (govt): grant, 201904 SBRI Healthcare funding for developm of cell therapy for osteoarthritis 2019-04-01
Cellnovo–NONE: investment, 201903 in administration 2019-03-28
Inivata–Consilium: public relations, 201903 service existent by CSC 2019-03-28
Inivata–LifeSci: public relations, 201903 service existent IR by LifeSci Advisors 2019-03-28
Univ College London–ArcherDx: PCR technology, 201903– collab €na use of AMP technology in UCL-sponsored UK lung cancer diagnostics TRACERx study 2019-03-28
Exscientia–Edelman: public relations, 201803 service existent by Edelman PR 2019-03-22
Celgene–Exscientia: drug discovery software, 201903–202203 collab $25m upfront + milestones + royalties 3y AI drug discovery partnership 2019-03-21
United Kingdom (govt)–Cambridge Cancer Genomics: personalised immuno-oncology, 201903– collab long-term of Genomics England + CCG.ai 2019-03-21
Verona Pharma–Novo Group: investment, 201903 existent investment Novo Holdings owns 11.76% shareholding in Verona Pharma plc 2019-03-21
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28  next pagenext page



Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top